Registration number: 07290804

ABB Pharmaceuticals Limited

Unaudited Abbreviated Accounts

Year Ended 30 June 2015



Page Kirk LLP
Chartered Accountants
Sherwood House
7 Gregory Boulevard
Nottingham
NG7 6LB

Contents

Accountants' Report	1
Abbreviated Balance Sheet	2
Notes to the Abbreviated Accounts	3
	4

Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts

Year Ended 30 June 2015

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of ABB Pharmaceuticals Limited for the year ended 30 June 2015 set out on pages 2 to 3 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at icaew.com/membershandbook.

This report is made solely to the Board of Directors of ABB Pharmaceuticals Limited, as a body, in accordance with the terms of our engagement letter dated 25 June 2010. Our work has been undertaken solely to prepare for your approval the accounts of ABB Pharmaceuticals Limited and state those matters that we have agreed to state to them, as a body, in this report in accordance with AAF 2/10 as detailed at icaew.com/compilation. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than ABB Pharmaceuticals Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that ABB Pharmaceuticals Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of ABB Pharmaceuticals Limited. You consider that ABB Pharmaceuticals Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of ABB Pharmaceuticals Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

lage Kirklur

Page Kirk LLP Chartered Accountants Sherwood House 7 Gregory Boulevard Nottingham NG7 6LB

11 March 2016

Abbreviated Balance Sheet

30 June 2015

			2015	201
	Note	£	£	£
Current assets				
Debtors			22,000	22,000
Cash at bank and in hand		•	7,190	7,23
		• • •	29,190	29,23
Creditors: Amounts falling due within one year			(61,974)	(61,16
Net liabilities			(32,784)	(31,926
Capital and reserves	•	*		
Called up share capital	2	52,000	•	52,000
Profit and loss account		(84,784)		(83,926)
Shareholders' deficit			(32,784)	(31,926

For the year ending 30 June 2015 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These abbreviated accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 11 March 2016 and signed on its behalf by:

Ms J L Bunyan

Director

Company registration number: 07290804

Notes to the Abbreviated Accounts

Year Ended 30 June 2015

1 Accounting policies

Basis of preparation

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (Effective April 2008).

Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability in the balance sheet. The corresponding dividends relating to the liability component are charged as interest expense in the profit and loss account.

2 Share capital

Allotted.	called-up	and fully	paid s	shares

Anotica, banca ap ana ranj	paid officios			
	20	2015		
	No.	£	No.	£
Ordinary of £1 each	52,000	52,000	52,000	52,000

3 Going concern

The company is in the process of developing products for eventual sale on the open market. The directors are supporting the company and undertake not to withdraw their capital for at least 12 months. As a result the company accounts are prepared on the going concern basis.